- LOGIN
- MemberShip
- 2026-04-13 10:24:10
- Policy
- Benefit for 46 generics for Eliquis will be kicked out
- by Kim, Jung-Ju Nov 22, 2021 05:52am
- BMS won the patent dispute between BMS' Eliquis (Apixaban) and it's generics, which had a patent dispute between companies due to generics released before the patent expired. Dozens of generics have been forced to withdraw their benefits. Generics will be legally removed from the list immediately on the 1st of next month due to the establishment of patent infringement, and the original drug, Eliquis, will return to its original price (upper limit price). According to the industry, the MOHW is pushing for a revision (proposal) of the drug benefit list. This lawsuit is a patent dispute after being released after listing the benefit before the expiration of the original patent. Patents related to Lactam-Containing Compounds and Derivatives thereof asFactor Xa Inhibitors' are valid until September 9, 2024. In the case of original drug prices, when generic is listed, prices fall under the collective drug price reduction system. Accordingly, a lawsuit was filed against the MOHW in July 2019 and has continued to this day. In December of the same year, the MOHW already won the first trial, but in April this year, a patent registration invalidation lawsuit against generic companies was reversed and remanded, and in August, BMS Korea won the case. Until now, coordination between the MOHW and BMS is still underway. The mediation plan included ▲ adjusted and announced by promptly proceeding with the Eliquis adjustment procedure,▲ deletion the benefits of the previously listed Apixaban products ▲transitional measures not applied to drugs that have been adjusted for non-reimbursement. The MOHW is sequentially taking follow-up measures accordingly. The number of Apixaban's generics currently listed on the list is 46 items. Generic price is 635 won per tablet. The government has decided to delete these drugs' benefit as of December 1. This is because drugs recognized for patent infringement cannot be sold immediately according to Article 13(4)5 and Article 13(4)16 of the "Rules on Standards for National Health Insurance Medical Care Benefits". Therefore, all of these drugs will not be available for sale on December 1st without any further transitional measures. At the same time, the original drug, Eliquis, recovers its existing drug price on the same date. This is because all competitive generics disappear as the patent court recognizes all generics for Eliquis as patent infringement drugs. The original price is 1,132 won per tablet as a result of the Price-Volume Agreement. However, the actual drug price of Eliquis in the field of medical institutions is expected to remain unchanged. Because when the legal battle for this drug began, the drug price remained unchanged because the company immediately applied for a suspension of execution and the court accepted.
- Policy
- Lixiana latecomers apply for approval as an ODT
- by Lee, Tak-Sun Nov 22, 2021 05:52am
- Latecomers of Daiichi Sankyo’s novel oral anti-coagulant (NOAC) ‘Lixiana (edoxaban tosylate hydrate)’ were found to have applied for approval to the Ministry of Food and Drug Safety. Although Lixiana’s substance patent does not expire until November 10th, 2026, with the PMS (post-marketing surveillance on new drugs) period expiring on August 24th, the companies have immediately applied for the approval of their latecomers. One characteristic of the latecomer drugs is that they are orally disintegrated tablets (ODT) that dissolve or disintegrate in the tongue without water. According to the MFDS on the 21st, other edoxaban tosylate hydrate products that contain the same ingredient as Lixiana applied for approval on August 25th. Latecomer drugs were blocked from applying for approval during Lixiana's PMS period, which lasted August 24th. Therefore, companies applied on the 25th, immediately one day after the end of the PMS period. On how many companies have applied for approval remains unknown. However, considering the number of companies that filed patent challenges, around 10 companies could have applied for approval at the same time, because the companies need to apply for the approval to receive first generic exclusivity. 10 companies including Boryung Pharmaceuticals have succeeded in avoiding Lixiana's composition patent (which lasts until August 21st, 2028). Boryung Pharmaceutical was the first to file a passive trial to confirm the scope of the patent in July 2018 and receive confirmation in July last year. Hanmi Pharmaceutical and Chong Kun Dang followed and received confirmation. The decision was finalized after the patentee Daiichi Sankyo did not file an appeal. However, Lixiana’s substance patent stays effective until November 10th, 2026, therefore the latecomer drugs will have to wait 5 more years before their release. The latecomer drugs that applied for approval this time are orally disintegrating tablets (ODT). On the other hand, Daiichi Sankyo’s Lixiana was approved in 3 doses, all in traditional tablet formulations. However, in Japan, Daiichi Sankyo had also released orally disintegrating tablet (ODT) formulation of Lixiana. ODTs dissolve in the mouth without water and is useful for older adult patients who have difficulty swallowing traditional oral tablets. However, unlike in Japan, the Korean market prefers traditional tablets over ODTs. Therefore, the latecomers' ODT formulations are interpreted to be a means to evade the composition patent rather than market preference. DongA-ST is already conducting a bioequivalence test for its latecomer ODT formulation. Lixiana is the lead product in the domestic NOAC market over other NOACs including Xarelto, Eliquis, and Pradaxa. The market recorded ₩17.2 billion in prescriptions in Q2 alone. Also, the anticoagulant treatment market was reorganized around NOACs, supporting the steady growth of the market. In line with the trend, domestic companies have been continuously knocking to enter the latecomer NOAC market. After many twists and turns, the Xarelto latecomer market opened its doors in October this year. Domestic latecomer companies are targeting clinics to expand sales as promotion of the original drug was focused around large hospitals.
- Company
- Prolonged delay in GSK vaccine supply may cost ₩30 bil
- by Nov 22, 2021 05:52am
- The discontinuation in the supply of many GSK vaccines is causing greater ripples. With the rising possibility that the situation may be prolonged, concerns continue over the sales gap, and procurement of substitutes is rising. GSK had announced the supply setbacks of 9 of its vaccines to primary clinics and hospitals on the 25th. The vaccines that were discontinued include: ▲Rotarix (rotavirus vaccine), ▲Cervarix (cervical cancer vaccine), ▲Synflorix (Pneumococcal conjugate vaccine), ▲Manveo (meningococcal conjugate vaccine), ▲Havrix (Hepatitis A vaccine), ▲Priorix (MMR vaccine), ▲Boostrix (Tdap vaccine), ▲Infanrix-IPV, IPV/Hib (DTaP vaccine) The supply of the vaccines was suspended due to errors found in the Common Technical Document while reviewing registration logs. Since the errors are documentation-related and unrelated to quality, GSK had said it will resume shipment after submitting supplementary documents. The problem lies in the possibility of the prolonged GSK supply gap. In the field, it is said that the delay may last up to 6 months at most considering the time necessary to prepare the supplementary documents and the MFDS review period. GSK’s revenue gap from the suspended products also seems inevitable. Annual sales of its main product, Rotarix, was ₩11.7 billion. In addition, Havrix sold ₩6.8 billion, Manveo ₩4.6 billion, Synfloris ₩4.1 billion, Cervarix ₩3.3 billion, and the annual sales of all 9 vaccines grossed to approximately ₩30 billion Also, many of the vaccines that were suspended supply belong to the National Immunization Program and may interfere with essential immunizations for infants and young children. To address this concern, the Korea Disease Control and Prevention Agency advised cross-vaccination with vaccines from other manufacturers. In general, cross-inoculation of vaccines that require multiple doses is not recommended, however, due to the delay that may occur for those who already received their first dose with GSK products, the cross-inoculation was approved as an exception. The situation is better for the DTaP vaccine Infanrix-IPV and IPV/Hib, and they can be substituted with Sanofi’s ‘Pnetaxim,’ ‘Tetraxim,’ Boryung’s ‘Boryung DTaP, IPV.’ However, other vaccines have only one option each as a substitute. The pneumococcal conjugate vaccine Synflorix can be substituted with Pfizer’s ‘Prevenar 13,’ cervical cancer vaccine Cervarix with MSD’s ‘Gardasil.’ The rotavirus vaccine Rotarix can be substituted with MSD’s ‘RotaTeq.’ The concern is that since most are imported products, procurement of the substitutes may be difficult. On this, GSK said, “We are unclear on how long the process will take, but the company will make the most effort to close the gap as soon as possible.” Also, MSD, which owns RotaTeq and Garadsil said, “We are closely monitoring the situation, and will do our best to prevent any disruptions arising in the domestic vaccine supply. Also, we will work closely with the government if necessary.”
- Company
- Yuhan has secured 260 billion won in technology fee in 3 yrs
- by Chon, Seung-Hyun Nov 22, 2021 05:52am
- Yuhan Corporation is creating a case of securing additional technology fees by advancing to the development stage even after exporting new drug technologies. It has secured a total of 260 billion won in new drug technology exports over the past 3 years. It has secured more money with additional technology fees than the down payment secured by exporting new drug technologies. According to the industry on the 17th, Yuhan Corporation will receive $10 million milestone for entering phase 1 clinical trials of YH25724, NASH treatment transferred to Beringer Ingelheim. YH25724 is a drug that Yuhan Corporation exported up to $870 million in technology to Beringer Ingelheim in July 2019. Under the terms of the contract, the down payment that is not obliged to return is $40 million. Yuhan Corporation received a total of $50 million in technology exports of YH25724. Yuhan Corporation is achieving results in acquiring additional technology fees by advancing to the development stage of technology export tasks. Yuhan Corporation has signed a total of five new drug technology export contracts since July 2018. In July 2018, it transferred YH14618 technology to Spine Biopharma, a treatment for degenerative disc disease. It received a down payment of $650,000 and was guaranteed $2175 million with step-by-step milestones based on development, permission and sales. Yuhan Corporation launched Janssen Biotech's anticancer drug in November 2018. Lazertinib' technology was exported. The total contract size, including $50 million in down payment, which is not obligated to return, is up to $1.25 billion. In January 2019, Gilead Science signed a license and joint development contract for new drug candidates acting on two drug targets for NASH treatment. It is a condition that receives a down payment of $15 million and receives $777 million milestones according to development, permission and sales. In August last year, it signed a technology transfer contract with Processa Pharmaceuticals in the United States for YH12852, a candidate for treating functional gastrointestinal diseases. Yuhan Corporation received a down payment of $2 million as a stock that was not obliged to return. Yuhan has secured additional technology fees four times due to progress in the development stage after exporting new drug technologies. Yuhan Corporation received Lazertinib's milestone of $35 million from Janssen in April last year. Janssen provided additional milestones to Yuhan Corporation at the time, starting clinical trials of combination therapy between Amivantamab and Lazertinib. Yuhan Corporation received an additional $65 million in additional milestones in November last year when it began recruiting subjects for a phase 3 clinical trial of Janssen's own anticancer drug Amivantamab and Lazertinib. YH25724, which Beringer Ingelheim started clinical trials this time, agreed to receive $10 million out of the $40 million down payment when the non-clinical toxicity test was completed, but received the remaining down payment last year. As a result, Yuhan Corporation has secured $2176.5 million (about 260 billion won), including additional milestones over the past three years. Of the technical fees received by Yuhan Corporation, milestones exceeded the down payment of $110 million. The technology fees secured by Yuhan Corporation are contributing to improving its performance. Yuhan Corporation has recognized technology fee profits for 11 consecutive quarters since the first quarter of 2019. The cumulative technology fee revenue reflected for two years and nine months amounted to 217.3 billion won.
- Company
- Viatris Korea will participate in the IMPACT WEEK
- by Eo, Yun-Ho Nov 22, 2021 05:52am
- Vitris Korea celebrated its first anniversary. On the 16th, Viatris announced that it will participate in the IMPACT WEEK designated by the world to mark the first anniversary of its launch, reflect on the past year, and carry out activities to commemorate the first anniversary with executives and employees. During Impact Week, Viartris will hold various events with executives and employees around the world under the theme of "Advancing Access: Everywhere Health Matters." On November 16th, U.S. time, an opening bell event and an outdoor advertisement campaign for the New York Times Square electronic display are scheduled to mark the first anniversary on the New York Stock Exchange. Linkedin Live discussion will also be held with various stakeholders to discuss ways to strengthen drug accessibility and events with the U.S. media the Hill. In addition, it plans to celebrate its first anniversary by communicating with Viatris employees around the world through the application. They will have time to express gratitude to employees around the world for their hard work over the past year and draw the future of Viatris together. In particular, Viatris Korea has time to express gratitude to employees and colleagues who have created our new journey together over the past year. Viatris Korea obtained domestic approval for MDR-TB tx Doveprella (Pretomanid) in October this year to increase access to patients in areas where unmet medical needs exist. Since domestic MDR-TB tx options have been limited over the past 50 years, it is meaningful in that it provides new treatment options to patients through the introduction of new treatments. In addition to Lipitor, Novasc, and Lyrica, Viatris Korea plans to realize its vision by expanding its portfolio to new treatment areas and enhancing accessibility. Lee Hye-young, CEO of Viatris Korea, said, "During the year of launch, the company has successfully adapted to the rapidly changing environment and has shown various results, and both the company and its employees are continuing a rewarding journey to become a 'company they want to work' with a new and healthy culture." In addition, she stressed, "As a new type of healthcare company, we will continue to do our best to contribute to the development of the domestic health care environment through active collaboration with various stakeholders." Meanwhile, Viatris is a global healthcare company launched in November 2020 by the combination of Upjohn and Mylan companies, which were Pfizer's business divisions, and was selected as Fortune Journal's 2021 Change the World in recognition of its accessibility to innovative HIV treatments over a decade.
- Policy
- AML drug that returned after 7 years is approved in Korea
- by Lee, Tak-Sun Nov 19, 2021 05:52am
- An acute leukemia treatment that withdrew its new drug application (NDA) and then was reapproved by the FDA in 2017 has now been approved in Korea. The drug is Pfizer’s ‘Mylotarg (gemtuzumab ozogamicin).’ On the 18th, the Ministry of Food and Drug Safety approved Prizer’s 'Mylotarg inj.4.5mg.’ The drug is indicated for the treatment of newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The approval gained attention because it was the second time the company received approval for the drug after voluntarily withdrawing its treatment from the market. Wyeth first received approval for Mylotarg in 2000. At the time, the drug received attention as the first antibody-drug conjugate (ADC) approved in the market. However, Pfizer, which acquired Wyeth in 2010, voluntarily withdrew Mylotarg’s FDA approval. In a clinical trial, the drug did not show clinical benefit and the rate of fatalities as a result of treatment-related toxicity was significantly higher in the Mylotarg arm compared to the chemotherapy arm. Then in 2017, Pfizer received approval from the FDA again for Mylotarg in response to the high demand among doctors for its use due to a limited amount of options being available for AML. For the new approval, the company demonstrated the efficacy of Mylotarg in a lower dose in an investigator-led trial. In the clinical trial (ALFA-0701) that was conducted on 271 patients aged between 50 to 70 with newly-diagnosed AML, the median event-free survival (period from the date of randomization to death from any cause, including induction therapy failure, recurrence, etc.) of patients who were treated with Mylotarg was 17.3 months for patients receiving Mylotarg, compared with the 9.5 months for those receiving chemotherapy alone. The MFDS approved the drug as an orphan drug and designated it as a Risk Management protocol (RMP) drug to monitor post-marketing adverse reactions.
- Policy
- The CSO reporting system will be reviewed
- by Lee, Jeong-Hwan Nov 19, 2021 05:52am
- A bill that mandates government reporting of drug sales and promotional agencies (CSOs) and a bill that regulates illegal hospital subsidies between hospitals, pharmacies, and agents in exchange for prescriptions will be reviewed by the National Assembly's subcommittee on the 24th.The government has also published a bill to designate late night operated pharmacies and support budgets, a survey of pharmacies illegally opened through license, and a bill to announce information on illegal pharmacies to the public. In order to strengthen regulations on illegal office managers' hospitals, a bill will also be reviewed to give the NHIS the authority to review the establishment of medical institutions and strengthen the authority to request data submission by the medical institution's opening review committee. On the 18th, Kim Min-seok, chairman of the National Assembly's welfare committee, and the ruling and opposition parties' secretaries agreed on the agenda of the 1st and 2nd Legislation Subcommittees containing such information. The first subcommittee on the bill, where major bills in the health and pharmaceutical sectors will be reviewed, will be held at 9 a.m. on the 24th. The first agenda to be reviewed is the CSO government reporting system bill proposed by Rep. Kim Sung-joo of the Democratic Party of Korea. The bill enforces government reporting by individual drug promoters or corporate CSOs and regulates that drug promotions cannot be entrusted if they are not reported. The goal of the bill is for CSO to improve the reality of illegal rebates. A revision to the Pharmaceutical Affairs Act, which further clarified CSO's regulations on banning rebates on illegal drugs and medical devices, was also listed on the second screening list. The bill is expected to be reviewed by Rep. Kang Byeongwon of the Democratic Party and Rep. Seo Jung-sook of the People's Power, respectively. A bill to support the designation and budget of public night operated pharmacies and local governments, proposed by Rep. Kim Do-eup, the People's Power, will also be reviewed. The key is to allow the Mayor/Do Governor or the Mayor/Gun/Gu Head to designate pharmacies operated during late-night hours and holidays, and to support expenses necessary for operation within budget. This is the same as the bill recently proposed by Democratic Party lawmaker Seo Young-seok, and the bill will be able to be pushed forward at the same time as the welfare committee has decided on a budget of KRW 4,041 billion for next year's pilot project. Rep. Seo Young-seok's proposal is unlikely to be reviewed with that of Kim Do-eup due to the late timing of the proposal, but the contents are similar, so there is a possibility that it will be implemented next year if the review opportunity is obtained. A survey of illegal pharmacies and herbal pharmacies represented by Rep. In Jae-geun of the Democratic Party of Korea and a bill to announce the results were also on the list. The purpose is to solve the problem of unfairly defrauding health insurance finances by opening a pharmacy where unlicensed people, not pharmacists, rent licenses. The main goal is to regularize surveys of illegal opening, operating pharmacies, and herbal pharmacies and disclose the results of illegal confirmation to the public. With the aim of tightening regulations on the hospital of the secretary, the NHIS staff will be included in the medical institution's opening committee, and the bill will also be reviewed to allow the NHIS to request necessary data or opinions. The two bills were submitted by Rep. Kang Byeongwon. A bill will also be reviewed to announce the results of an investigation into illegal pharmacies (herbal pharmacies) proposed by Rep. In Jae-geun of the Democratic Party. The purpose is to solve the problem of unlicensed people, not pharmacists, opening licensed rental pharmacies to unfairly defraud health insurance finances. The main goal is to regularize surveys of illegal opening, operating pharmacies, and herbal pharmacies and disclose the results of illegal confirmation. The government is expected to strengthen its obligation to ventilate medical institutions to prepare for quarantine such as COVID-19, and revise the Medical Service Act to raise the level of regulations on illegal medical advertisements.
- Policy
- Is Celltrion developing a combination of HBP?
- by Lee, Tak-Sun Nov 19, 2021 05:51am
- Attention is focusing on whether Celltrion, which has secured domestic copyrights for ARB-based hypertension treatment Edarbi (Azilsartan Medoxomil), will develop a combination that combines Edarbi and Amlodipine. Attention is focusing on whether Celltrion will also stand out in the hypertension treatment market, which is the domain of traditional pharmaceutical companies. The Ministry of Food and Drug Safety approved the plan which Celltrion applied to verify the effectiveness and safety of Azilsartan Medoxomil and Amlodipine Besylate for eight weeks on the 17th. This test is a multicenter, randomized, double-blinded test to compare the effectiveness and safety of 8-week combined administration in patients with essential hypertension who do not respond appropriately to each of Azilsartan Medoxomil and Amlodipine Besylate. Seoul National University Hospital plans to conduct 852 test subjects in Korea. The industry believes that this test first verifies the effectiveness of the combination of Azilsartan Medoxomil and Amlodipine Besylate for the development. It is known that combination of Azilsartan Medoxomil and Amlodipine Besylate has already been commercialized and sold in Japan. However, it has not yet been approved for items in Korea. Edarbi was approved in Korea in 2017, and Edarbyclor, which combines Chlorhalidone, a diuretic, was approved the following year. Celltrion invested about 307.4 billion won last year to buy 18 kinds of medicines owned by Takeda in the Asia-Pacific region. This also includes Edarbi, a treatment for hypertension. Edarbi has been sold by Dong-A ST, a domestic partner, since it was approved in Korea. However, it is the ninth ARB-based new drug released in Korea, and has struggled in the market dominated by selected drugs. As of last year, the amount of outpatient prescriptions was 8.2 billion won according to UBIST, which is still less than the blockbuster standard of 10 billion won. The development of this combination system is interpreted as an attempt to increase the domestic market share by expanding the product lineup. Celltrion is competing with traditional pharmaceutical companies in the domestic synthetic drug market, but its main business is also biosimilar. Celltrion also has a blockbuster called Godex, but Edarbi is the first hypertensive new drug.The hypertension treatment market is not an easy market because existing pharmaceutical companies are fiercely competing in Clinics. Attention is focusing on whether Celltrion, which is seeking global big perm through biosimilars, will show its presence as Edarbi.
- Policy
- Competition intensifies in Forsteo market with 4 latecomers
- by Lee, Tak-Sun Nov 19, 2021 05:51am
- Teriparatide products Fosteo and TeriboneProducts with the same ingredient as the world’s first bone anabolic agent 'Forsteo(Teriparatide),' which was finally able to receive reimbursement in Korea 10 years after its approval, are rapidly entering the market. Domestic pharmaceutical companies are occupying the follow-on market with their Forsteo latecomers. Already 4 teriparatide products have entered the market. On the 16th, the MFDS approved Pharmbio Korea’s teriparatide biosimilar. The product contains the same teriparatide ingredient as Forster and is indicated for the treatment of osteoporosis in women and men. The drug was approved as a biosimilar after demonstrating its bioequivalence to Forsteo. Forsteo is Lilly Korea’s osteoporosis treatment that was approved in 2002. As the first bone anabolic(bone-forming) agent, Forsteo received much attention for its different treatment mechanism from existing antiresorptive agents. Previous bone resorption inhibitors had inhibited the release of calcium from the bone into the bloodstream, however, Forsteo, as an anabolic agent, promoted proliferation and activity of osteoblasts that are involved in new bone formation. It took 10 years for the drug after being approved in 2006 to receive reimbursement. Forsteo was approved for reimbursement as second-line treatment in 2016. However, patients who showed no effect or are unable to use one or more of the existing bone resorption inhibitors are allowed reimbursement for Forsteo. Since receiving reimbursement, Forsteo defeated the then-leading bisphosphonate products in the market and become the top leader in the market. Domestic pharmaceutical companies quickly followed on its course with their biosimilars. Dong-A ST was the first to be approved for its more convenient, single, once-weekly injection formulation of the same ingredient, ‘Teribone subcutaneous inj.’ in 2015. In 2019, Daewon Pharm was the first to be approved for Forsteo’s biosimilar, ‘Terrosa Cartridge.’ And last year, BMI Korea was approved for Teribone’s biosimilar, ‘Teria inj,’ sparking full competition in the market. And the recent introduction of PharmBio’s second Forsteo biosimilar increases the count of teriparatide products to 4. Based on IQVIA, Forsteo sold ₩17.1 billion, Teribone ₩2 billion, Terossa ₩0.8 billion last year. Forsteo continued to show strength as the original by ranking second in the osteoporosis treatment market, but the latecomers still have a long way to catch up due to their late entry. However, this does not mean that Forsteo’s has a solid lead over its competitors because of the large gap between Forsteo and the market leader 'Prolia (₩75.1 billion).' Prolia is a biologic bone resorption inhibitor that is administered once every 6 months and is considered to have upgraded the effect and convenience in administration over existing osteoporosis treatments. In particular, Prolia’s reimbursement was extended to first-line from April 2019, showing an advantage over Forsteo in market competitiveness as it is still only reimbursed in the second-line. This is why there are some negative outlooks on the market performance of Forsteo latecomers. However, there is also analysis that the drugs will show strength in the market if reimbursement is expanded to first-line.
- Policy
- A law, proposed to prohibit overuse of drug price reduction
- by Lee, Jeong-Hwan Nov 19, 2021 05:51am
- The ruling party has proposed an additional bill to regulate the abuse of lawsuits by some pharmaceutical companies, including an injunction to suspend execution of the government's drug price cut. Following Rep. Kim Woni of the Democratic Party of Korea, Rep. Nam In-soon also proposed a partial amendment to the National Health Insurance Act on the 17th. The key point of the bill submitted by Rep. Nam In-soon is to allow the NHIS to collect a significant portion of health insurance losses from drug companies and others if it is confirmed that it is not illegal depending on the outcome of the drug price reduction lawsuit. If the suspension of execution is rejected and the ruling is confirmed to be illegal, the NHIS will pay the losses suffered by pharmaceutical companies. Rep. Nam In-soon explained, "There have been 46 cases of administrative trial claims and administrative litigation over the past 10 years against the reduction in drug prices under the current law. Administrative litigation to benefit from the suspension of execution is on the rise." Rep. Nam said, "As most of the suspension of pharmaceutical companies' applications is cited by the Administrative Appeals Committee or courts, drug price cuts are not executed during the trial or litigation period." She pointed out, "The problem is that even if it is confirmed that the disposition is not illegal in the trial or lawsuit on the merits in the future, pharmaceutical companies enjoy the economic benefits of not being executed during the lawsuit." Rep. Nam said, "The financial loss of health insurance due to abuse of lawsuits reached 160 billion won as of June this year, which was also pointed out in last year and this year's parliamentary audits." She said, "We have pushed for a revision of the law to prevent financial losses in health insurance due to abuse of administrative trials and administrative litigation related to drug prices and compensate for losses from manufacturers and others for illegal dispositions."
